Sotera Health (NASDAQ:SHC) Issues FY 2026 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.950-1.010 for the period, compared to the consensus earnings per share estimate of 0.950. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Sotera Health Trading Down 0.2%

Shares of SHC traded down $0.03 during mid-day trading on Friday, reaching $18.88. The company’s stock had a trading volume of 410,604 shares, compared to its average volume of 2,863,214. Sotera Health has a 52 week low of $12.94 and a 52 week high of $19.85. The stock has a market cap of $5.38 billion, a PE ratio of 46.16 and a beta of 1.77. The company’s fifty day moving average price is $17.07 and its two-hundred day moving average price is $16.31. The company has a current ratio of 2.82, a quick ratio of 2.54 and a debt-to-equity ratio of 3.56.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Thursday, August 6th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a net margin of 9.91% and a return on equity of 39.73%. The company had revenue of $321.38 million for the quarter, compared to analysts’ expectations of $309.70 million. During the same quarter last year, the company earned $0.20 EPS. The firm’s revenue was up 9.2% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, analysts predict that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SHC. Weiss Ratings upgraded Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 9th. Barclays reiterated an “overweight” rating on shares of Sotera Health in a report on Friday. Citigroup reissued a “buy” rating on shares of Sotera Health in a report on Friday. UBS Group set a $19.00 price objective on shares of Sotera Health in a research report on Wednesday, June 24th. Finally, Wall Street Zen downgraded shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.25.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.36% of the stock is currently owned by company insiders.

Key Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted EPS was $0.26 versus the $0.24 consensus, while revenue rose 9.2% year over year to $321.4 million, surpassing estimates of $309.7 million. Adjusted EPS increased 30% from $0.20 a year earlier. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised 2026 guidance: Sotera Health increased its revenue-growth outlook to 5.25%-6.75% and Adjusted EBITDA growth outlook to 5.75%-7.25% on a constant-currency basis. Adjusted EPS guidance is now $0.95-$1.01, compared with the $0.95 analyst consensus. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Growth was broad-based: Sterigenics revenue increased 7.0% on a constant-currency basis, Nordion grew 16.7%, and Nelson Labs grew 5.4%. Adjusted EBITDA rose 10%, the margin expanded to 51.6%, and operating cash flow reached $88 million for the quarter. The company also repriced its term loan, expected to save approximately $3.5 million in annual interest expense, and completed the final private-equity sponsor secondary offering. Sotera Health Reports Strong Q2 2026 Results and Raises Full-Year Outlook
• Neutral Sentiment: Balance-sheet risks remain: Total debt was approximately $2.2 billion, though the net leverage ratio improved to 3.0x and liquidity was approximately $950 million. Investors will also continue monitoring inflationary costs, ethylene oxide supply and regulatory exposure, as well as litigation related to ethylene oxide emissions. Sotera Health Q2 2026 Earnings Call Transcript

Institutional Investors Weigh In On Sotera Health

Several hedge funds have recently made changes to their positions in SHC. ION Fund Management Ltd bought a new position in Sotera Health during the 4th quarter valued at approximately $176,000. Amundi bought a new position in Sotera Health in the 4th quarter worth about $179,000. Maryland State Retirement & Pension System purchased a new stake in Sotera Health during the 4th quarter valued at about $176,000. Integrated Wealth Concepts LLC bought a new position in shares of Sotera Health in the fourth quarter worth approximately $192,000. Finally, Focus Partners Advisor Solutions LLC bought a new position in Sotera Health in the 4th quarter valued at approximately $194,000. 91.03% of the stock is currently owned by institutional investors.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.